Tag: IPO

INDIANAPOLIS – Apria Healthcare has announced the launch of its initial public offering of 7.5 million shares of its common stock, with an initial offering price expected to be between $19 - $21 per share. The selling stockholders expect to grant the underwriters a 30-day option to purchase up to an additional 1.125 million shares of common stock. Apria will not receive any net proceeds from the sale of its common stock by the selling stockholders, including from any exercise by...

LAKE FOREST, Calif. – After a lengthy period of relative quiet, Apria Healthcare’s planned IPO could signal a company that is ready to grow, say M&A analysts.  The provider on Jan. 15 filed a Form S-1 with the Securities and Exchange Commission, a step it must take before filing an initial public offering.  “They’ve been a bit conspicuous by their absence in doing transactions,” said Jonathan Sadock, managing partner/CEO of Paragon...

NEW YORK and PLYMOUTH MEETING, Pa. - DFB Healthcare Acquisitions Corp. has closed on its merger with AdaptHealth Holdings. The combined company, which has been renamed AdaptHealth Corp., expected its Class A common stock and public warrants to list on the Nasdaq Capital Market under the new trading symbols AHCO and AHCOW, respectively, on Nov. 11. “(CEO Luke McGee) and his team have built one of the industry's leading HME providers through a combination of accretive capital deployment; high-touch...

When AdaptHealth's plan to become a public company was announced in July, ears perked up throughout the HME industry. New IPO listings by DME providers are rare. That could change following Adapt's IPO. To recap, Adapt will combine with DFB Healthcare Acquisitions Corp., which is currently traded on the NASDAQ under symbols DFBH and DFBHW. Once the combination of companies is completed, it is expected that DFB will change its name to AdaptHealth Holding Corp. and remain listed on the NASDAQ under...

MINNEAPOLIS ­- Inspire Medical Systems plans to raise $75 million by offering 5 million shares at a price range of $14 to $16 as part of an initial public offering that it announced earlier this month. Insiders plan to purchase $15 million worth of shares in the IPO, according to Nasdaq. Inspire Medical Systems, which plans to list on the New York Stock Exchange under the symbol INSP, makes FDA-approved neurostimulation technology that provides treatment for moderate to severe obstructive sleep...

MINNEAPOLIS - Inspire Medical Systems, the maker of FDA-approved neurostimulation technology that provides treatment for moderate to severe OSA, has filed paperwork for an initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Inspire has applied to list its common stock on the New York Stock Exchange under the ticker symbol “INSP.” BofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as...

DUDERSTADT, Germany - Ottobock has attracted interest from private equity firms, including KKR and CVC, according to Reuters. The firms are looking for a 20% stake in the company core business of making artificial limbs. Ottobock is also drawing interest from buyout firms BC Partners and Advent. The company is targeting PE firms, affluent families and technology funds as potential buyers in a deal it hopes to complete by the end of June, ahead of a planned initial public offering, Reuters reported....

LONDON - ConvaTec on Wednesday raised nearly $1.8 billion in London's biggest initial public offering of 2016, according to news reports. The company, which manufactures ostomy, wound, skin, continence and other critical care products, will use the proceeds from the IPO to redeem or repay debt. ConvaTec's shares traded just below their offer price of $2.76, at $2.75. The IPO represents about 33.8% of the company's stock, assuming no exercise of an overallotment option, and will rise to 38.9% if the...

GOLETA, Calif. - Inogen hopes to raise $75 million in its IPO by offering 4.4 million shares—20% insider—at $16 to $18 per share, according to news reports. At the midpoint of its proposed price range, its fully diluted market value would be $342 million, Renaissance Capital reports. For the 12 months ended Sept. 30, 2013, the portable oxygen concentrator manufacturer/provider reported $70 million in sales. Inogen filed for the IPO in November. It plans to trade on the NASDAQ under the...

GOLETA, Calif. - Inogen's Nov. 27 filing for a proposed initial public offering (IPO) provides a window into the inner workings of the company, including its direct-to-consumer strategy and its financial viability.Inogen lists its direct-to-consumer strategy as one of its main strengths, setting it apart from other HME manufacturers and helping it to grow revenue from $10.7 million in 2009 to $48.6 million in 2012. The company adopted the strategy in 2009, after receiving pushback from HME providers...